Agreed TB. Investors have 2 choices - trust the team and accept...

Agreed TB.

Investors have 2 choices - trust the team and accept they know what they signed up for.... or don't. It seems a lot of long term holders have sold recently so I'm certainly not saying management should be trusted. But that's the choice.

Debating trial data is probably beyond this forum. Trying to interpret trial data and trial progress is a rabbit hole that few are qualified to jump down - so unfortunately we need to either get PHD in Oncology (and jump in the hole), or join the dots.

The data Bijal Shah is summarizing predates IMU's phase 1b trial and would have been available last year. IMU have done their DD, then proceeded with the licence and thereafter, on record, IMU have said the drug demonstrates safety and has received encouraging FDA guidance etc. As below. So - trust management or not?